Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Dupilumab (SAR231893)

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Sanofi

Target Recruit Count: 182

Registration Number: NCT05976386

Locations: 🇺🇸
Clinical Pharmacology of Miami-Site Number:8400001, Miami, Florida, United States

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Dupilumab (SAR231893)

First Posted Date: 2023-08-04

Last Posted Date: 2023-08-04

Lead Sponsor: Sanofi

Target Recruit Count: 38

Registration Number: NCT05976360

Locations: 🇺🇸
Prism Research-Site Number:840002, Saint Paul, Minnesota, United States
🇺🇸
Biokinetic Clinical Applications-Site Number:840003, Springfield, Missouri, United States

A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria

Phase 1

Recruiting

Conditions: Phenylketonuria

Interventions: Drug: SAR444836

First Posted Date: 2023-08-02

Last Posted Date: 2025-04-29

Lead Sponsor: Sanofi

Target Recruit Count: 32

Registration Number: NCT05972629

Locations: 🇺🇸
University of California San Francisco - Parnassus Heights- Site Number : 8400007, San Francisco, California, United States
🇺🇸
University of Florida College of Medicine- Site Number : 8400010, Gainesville, Florida, United States
🇺🇸
Children's Hospital Colorado - Aurora- Site Number : 8400015, Aurora, Colorado, United States

and more 7 locations

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A

Recruiting

Conditions: Hemophilia A

Interventions: Drug: Efanesoctocog Alfa BIVV001

First Posted Date: 2023-06-22

Last Posted Date: 2025-05-14

Lead Sponsor: Sanofi

Target Recruit Count: 200

Registration Number: NCT05911763

Locations: 🇺🇸
Banner MD Anderson Cancer Center- Site Number : 8400008, Gilbert, Arizona, United States
🇺🇸
Loma Linda University Health- Site Number : 8400015, Loma Linda, California, United States
🇺🇸
Orthopedic Institute for Children- Site Number : 8400004, Los Angeles, California, United States

and more 24 locations

Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight)

Not Applicable

Completed

Conditions: Gaucher Disease

Interventions: Procedure: Investigational procedure

First Posted Date: 2023-06-18

Last Posted Date: 2024-11-19

Lead Sponsor: Sanofi

Target Recruit Count: 13

Registration Number: NCT05908656

Locations: 🇺🇸
University of Florida 655 W 8th St- Site Number : 8400003, Gainesville, Florida, United States
🇺🇸
Metropolitan Hospital Center- Site Number : 8400001, New York, New York, United States
🇺🇸
Aurora Research Institute LLC- Site Number : 8400002, Milwaukee, Wisconsin, United States

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

Phase 2

Recruiting

Conditions: Alpha 1-Antitrypsin Deficiency
Emphysema

Interventions: Drug: SAR447537

First Posted Date: 2023-06-09

Last Posted Date: 2025-05-15

Lead Sponsor: Sanofi

Target Recruit Count: 130

Registration Number: NCT05897424

Locations: 🇺🇸
University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama, United States
🇺🇸
St. Joseph's Hospital and Medical Center- Site Number : 126, Phoenix, Arizona, United States
🇺🇸
David Geffen School of Medicine at UCLA- Site Number : 124, Los Angeles, California, United States

and more 38 locations

Dupilumab in Chinese Adult Participants With CRSwNP

Phase 3

Completed

Conditions: Chronic Rhinosinusitis With Nasal Polyps

Interventions: Drug: Placebo
Drug: Dupilumab
Drug: Budesonide

First Posted Date: 2023-05-26

Last Posted Date: 2024-12-17

Lead Sponsor: Sanofi

Target Recruit Count: 63

Registration Number: NCT05878093

Locations: 🇨🇳
Investigational Site Number : 1560016, Jinan, China
🇨🇳
Investigational Site Number : 1560001, Beijing, China
🇨🇳
Investigational Site Number : 1560010, Chengdu, China

and more 15 locations

Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single and Repeated Doses of SAR444336 in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: SAR444336

First Posted Date: 2023-05-25

Last Posted Date: 2023-12-22

Lead Sponsor: Sanofi

Target Recruit Count: 76

Registration Number: NCT05876767

Locations: 🇳🇱
Investigational Site Number :5280002, Groningen, Netherlands
🇳🇱
Investigational Site Number :5280001, Leiden, Netherlands

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: SAR441566

First Posted Date: 2023-05-15

Last Posted Date: 2023-08-21

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT05858788

Locations: 🇺🇸
Parexel International-Site Number:8400001, Glendale, California, United States

Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema

Phase 2

Active, not recruiting

Conditions: Alpha 1-Antitrypsin Deficiency
Emphysema

Interventions: Drug: SAR447537
Drug: Zemaira

First Posted Date: 2023-05-12

Last Posted Date: 2025-01-16

Lead Sponsor: Sanofi

Target Recruit Count: 99

Registration Number: NCT05856331

Locations: 🇺🇸
University of Alabama at Birmingham- Site Number : 105, Birmingham, Alabama, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
St Joseph's Hospital and Medical Center- Site Number : 126, Phoenix, Arizona, United States

and more 78 locations

Home Terms & Conditions Privacy Policy